Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glycosomal glyceraldehyde-3-phosphate dehydrogenase is an isoenzyme of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) that is specifically localized within glycosomes—specialized peroxisome-like organelles found in trypanosomatid protozoa such as Leishmania and Trypanosoma. This enzyme catalyzes a crucial step in glycolysis: the NAD⁺-dependent oxidation and phosphorylation of glyceraldehyde 3-phosphate to 1,3-bisphosphoglycerate. The glycosomal isoenzyme possesses unique sequence features, such as peptide insertions, a carboxy-terminal glycosomal targeting signal, and an excess of positive charges, distinguishing it from its cytosolic counterpart and from human GAPDH. Glycosomal GAPDH is essential for ATP production in trypanosomatids and is under investigation as a drug target since its inhibition may selectively disrupt parasite viability without affecting human cells.
Inhibitors would act by blocking glycolytic ATP production in parasites, leading to energy deprivation and death of the pathogen
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glycosomal glyceraldehyde-3-phosphate dehydrogenase (GAPDH (glycosomal), or gGAPDH (sometimes specifically for the glycosomal isoform)).